sotrovimab

LONDON and SAN FRANCISCO, Dec. 17, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commission (EC)…

British drugmaker GSK said on Tuesday its antibody-based COVID-19 therapy with U.S. partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant,…

"Based on the sequence of the Omicron variant, we believe sotrovimab is likely to maintain activity and potency against this variant," the company said in a statement. …

 – Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron –…

– US government contracts for approximately $1 billion1 (USD) now in place to purchase sotrovimab, further expanding access nationwide – – This brings the total number of doses secured…

– COMET-TAIL Phase 3 data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations…

By JoNel Aleccia For months, Joelle Ruppert was among the millions of Americans who are covid vaccine holdouts. Her reluctance, she said, was not so much that she opposed the new…